| Epidemiological model parameter | Value or range used | Data source | |
| HCV prevalence overall | 17.3% (13.2% to 22.0%) | Survey data | |
| HCV prevalence among injectors ⩽2 years | 14.5% (7.7% to 23.9%) | Survey data | |
| HCV prevalence among injectors >2 years | 18.2% (13.3% to 24.1%) | Survey data | |
| HCV prevalence if syringe share by source of most syringes: | |||
| Pharmacy, shop, hospital, health worker | 17.3% (8.9% to 25.7%) | Survey data | |
| Found, IDU, drug dealer, friend, etc | 23.1% (11.2% to 34.9%) | Survey data | |
| HIV prevalence overall | 2.7% (1.2% to 5.2%) | Survey data | |
| Prevalence of HCV among HIV positives | 100% (63.1% to 100%) | Survey data | |
| Prevalence of HCV among HIV negatives | 15.0% (11.1% to 19.6%) | Survey data | |
| Prevalence of HCV in general population* | 6.2% (4.4% to 8.5%) | Reference 21 | |
| Year HIV introduced into Rawalpindi | 1995–2005 | References 13, 14, 17, 37 |
HCV, hepatitis C virus; IDU, intravenous drug user.
Values in parentheses are 95% confidence intervals.
*Not used for fitting model, but assumed to be the HCV prevalence of newly initiated injecting drug users.